Wen-Long Liu
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Wen-Long Liu has a total of 35 co-authors. Here are the top co-authors by number of shared publications:
- Si-Yong Qin
Hubei Engineering Technology Research Centre of Energy Polymer Materials, School of Chemistry and Materials Science, South-Central Minzu University, Wuhan 430074, China; Key Laboratory of Analytical Chemistry of the State Ethnic Affairs Commission, School of Chemistry and Materials Science, South-Central Minzu University, Wuhan 430074, China
4 shared publications - Yin-Jia Cheng
Key Laboratory of Catalysis and Energy Materials Chemistry of Ministry of Education & Hubei Key Laboratory of Catalysis and Materials Science, School of Chemistry and Materials Science, South-Central Minzu University, Wuhan 430074, China
4 shared publications Hao-Ran Li
Key Laboratory of Catalysis and Energy Materials Chemistry of Ministry of Education & Hubei Engineering Technology Research Centre of Energy Polymer Materials, School of Chemistry and Materials Science
3 shared publicationsMei-Zhen Zou
School of Bioengineering and Health
3 shared publications- Xian-Zheng Zhang
Wuhan University
3 shared publications Yuan Huo
Key Laboratory of Catalysis and Energy Materials Chemistry of Ministry of Education & Hubei Engineering Technology Research Centre of Energy Polymer Materials, School of Chemistry and Materials Science
3 shared publications
Latest Publications
- 24 January 2026
- Published by American Chemical Society (ACS) in ACS Applied Nano Materials
- Vol. 9 (5) , 2321-2332
Polydopamine-Engineered TiO 2 Nanocomposites for Photothermally Enhanced Sonodynamic Tumor Therapy
- 24 January 2026
- Published by American Chemical Society (ACS) in ACS Applied Nano Materials
- Vol. 9 (5) , 2321-2332
Polydopamine-Engineered TiO 2 Nanocomposites for Photothermally Enhanced Sonodynamic Tumor Therapy
- 16 July 2025
- Published by American Chemical Society (ACS) in ACS Applied Bio Materials
- Vol. 8 (8) , 6830-6842
Hyperthermia-Accelerated Ion-Radical Production for Enhanced Tumor Nanocatalytic Therapy with Inhibition of Tumor Growth and Recurrence
Breast cancer is a significant health concern for women, and traditional chemotherapy, while effective, comes with harsh side effects and high recurrence rates. This necessitates the exploration of alternative therapeutic strategies. Photothermal therapy (PTT) offers a promising alternative, but its limited penetration depth hinders its efficacy in deeper tumors. This study designs a photothermal-enhanced nanocatalytic medicine, AF@mPDA@HA, that combines the advantages of PTT and nanocatalytic medicine to improve therapeutic outcomes. The system utilizes mesoporous polydopamine (mPDA) as a photothermal agent and a carrier of iron ions (Fe3+) and ammonium persulfate (APS), while hyaluronic acid (HA) provides a protective coating to prevent premature drug release and improve targeting to tumor tissues. APS shows higher affinity and reaction rate with ferrous ion than H2O2, as alternative of H2O2 as catalytic medicine. Once AF@mPDA@HA accumulated at the tumor site, PTT-induced hyperthermia promotes released APS and Fe3+ penetration into the deep tumor. The presence of reduced glutathione (GSH) in tumor converts iron ions to ferrous ions, which then react with APS to produce sulfate radicals (SO4-•). The photothermal effect further expedites this reaction, boosting the overall therapeutic efficacy. This multifunctional nanoplatform overcomes the limitations of current treatments and provides an ideal advancement in breast cancer therapy.
- 16 July 2025
- Published by American Chemical Society (ACS) in ACS Applied Bio Materials
- Vol. 8 (8) , 6830-6842
Hyperthermia-Accelerated Ion-Radical Production for Enhanced Tumor Nanocatalytic Therapy with Inhibition of Tumor Growth and Recurrence
Breast cancer is a significant health concern for women, and traditional chemotherapy, while effective, comes with harsh side effects and high recurrence rates. This necessitates the exploration of alternative therapeutic strategies. Photothermal therapy (PTT) offers a promising alternative, but its limited penetration depth hinders its efficacy in deeper tumors. This study designs a photothermal-enhanced nanocatalytic medicine, AF@mPDA@HA, that combines the advantages of PTT and nanocatalytic medicine to improve therapeutic outcomes. The system utilizes mesoporous polydopamine (mPDA) as a photothermal agent and a carrier of iron ions (Fe3+) and ammonium persulfate (APS), while hyaluronic acid (HA) provides a protective coating to prevent premature drug release and improve targeting to tumor tissues. APS shows higher affinity and reaction rate with ferrous ion than H2O2, as alternative of H2O2 as catalytic medicine. Once AF@mPDA@HA accumulated at the tumor site, PTT-induced hyperthermia promotes released APS and Fe3+ penetration into the deep tumor. The presence of reduced glutathione (GSH) in tumor converts iron ions to ferrous ions, which then react with APS to produce sulfate radicals (SO4-•). The photothermal effect further expedites this reaction, boosting the overall therapeutic efficacy. This multifunctional nanoplatform overcomes the limitations of current treatments and provides an ideal advancement in breast cancer therapy.
- 27 December 2023
- Published by American Chemical Society (ACS) in ACS Applied Nano Materials
- Vol. 7 (1) , 957-965
Hydrogen-Peroxide-Independent Chemodynamic Therapy via Docosahexaenoic-Acid-Hydroperoxide-Rich-Cytomembrane-Coated Magnetic Nanoparticles
- 27 December 2023
- Published by American Chemical Society (ACS) in ACS Applied Nano Materials
- Vol. 7 (1) , 957-965
Hydrogen-Peroxide-Independent Chemodynamic Therapy via Docosahexaenoic-Acid-Hydroperoxide-Rich-Cytomembrane-Coated Magnetic Nanoparticles
- 22 April 2022
- Published by Royal Society of Chemistry (RSC) in Chemical Communications
- Vol. 58 (42) , 6227-6230
A nanodevice with lifetime-improved singlet oxygen for enhanced photodynamic therapy
A nanodevice was designed with functions of singlet oxygen production, storage and release to improve the lifetime of singlet oxygen for enhancing photodynamic therapy.
- 22 April 2022
- Published by Royal Society of Chemistry (RSC) in Chemical Communications
- Vol. 58 (42) , 6227-6230
A nanodevice with lifetime-improved singlet oxygen for enhanced photodynamic therapy
A nanodevice was designed with functions of singlet oxygen production, storage and release to improve the lifetime of singlet oxygen for enhancing photodynamic therapy.
- 25 March 2019
- Published by Wiley in Advanced Materials
- Vol. 31 (18) , e1900499
Expandable Immunotherapeutic Nanoplatforms Engineered from Cytomembranes of Hybrid Cells Derived from Cancer and Dendritic Cells
Using the cytomembranes (FMs) of hybrid cells acquired from the fusion of cancer and dendritic cells (DCs), this study offers a biologically derived platform for the combination of immunotherapy and traditional oncotherapy approaches. Due to the immunoactivation implicated in the cellular fusion, FMs can effectively express whole cancer antigens and immunological co‐stimulatory molecules for robust immunotherapy. FMs share the tumor's self‐targeting character with the parent cancer cells. In bilateral tumor‐bearing mouse models, the FM‐coated nanophotosensitizer causes durable immunoresponse to inhibit the rebound of primary tumors post‐nanophotosensitizer‐induced photodynamic therapy (PDT). The FM‐induced immunotherapy displays ultrahigh antitumor effects even comparable to that of PDT. On the other hand, PDT toward primary tumors enhances the immunotherapy‐caused regression of the irradiation‐free distant tumors. Consequently, both the primary and the distant tumors are almost completely eliminated. This tumor‐specific immunotherapy‐based nanoplatform is potentially expandable to multiple tumor types and readily equipped with diverse functions owing to the flexible nanoparticle options.
- 25 March 2019
- Published by Wiley in Advanced Materials
- Vol. 31 (18) , e1900499
Expandable Immunotherapeutic Nanoplatforms Engineered from Cytomembranes of Hybrid Cells Derived from Cancer and Dendritic Cells
Using the cytomembranes (FMs) of hybrid cells acquired from the fusion of cancer and dendritic cells (DCs), this study offers a biologically derived platform for the combination of immunotherapy and traditional oncotherapy approaches. Due to the immunoactivation implicated in the cellular fusion, FMs can effectively express whole cancer antigens and immunological co‐stimulatory molecules for robust immunotherapy. FMs share the tumor's self‐targeting character with the parent cancer cells. In bilateral tumor‐bearing mouse models, the FM‐coated nanophotosensitizer causes durable immunoresponse to inhibit the rebound of primary tumors post‐nanophotosensitizer‐induced photodynamic therapy (PDT). The FM‐induced immunotherapy displays ultrahigh antitumor effects even comparable to that of PDT. On the other hand, PDT toward primary tumors enhances the immunotherapy‐caused regression of the irradiation‐free distant tumors. Consequently, both the primary and the distant tumors are almost completely eliminated. This tumor‐specific immunotherapy‐based nanoplatform is potentially expandable to multiple tumor types and readily equipped with diverse functions owing to the flexible nanoparticle options.
- Top Cited Papers
- 17 July 2018
- Published by Wiley in Advanced Materials
- Vol. 30 (35) , e1802006
Aggressive Man‐Made Red Blood Cells for Hypoxia‐Resistant Photodynamic Therapy
Extreme hypoxia of tumors represents the most notable barrier against the advance of tumor treatments. Inspired by the biological nature of red blood cells (RBCs) as the primary oxygen supplier in mammals, an aggressive man‐made RBC (AmmRBC) is created to combat the hypoxia‐mediated resistance of tumors to photodynamic therapy (PDT). Specifically, the complex formed between hemoglobin and enzyme‐mimicking polydopamine, and polydopamine‐carried photosensitizer is encapsulated inside the biovesicle that is engineered from the recombined RBC membranes. The mean corpuscular hemoglobin of AmmRBCs reaches about tenfold as high as that of natural RBCs. Owing to the same origin of outer membranes, AmmRBCs share excellent biocompatibility with parent RBCs. The introduced polydopamine plays the role of the antioxidative enzymes existing inside RBCs to effectively prevent the oxygen‐carrying hemoglobin from the oxidation damage during the circulation. This biomimetic engineering can accumulate in tumors, permit in situ efficient oxygen supply, and impose strong PDT efficacy toward the extremely hypoxic tumor with complete tumor elimination. The man‐made pseudo‐RBC shows potentials as a universal oxygen‐self‐supplied platform to sensitize hypoxia‐limited tumor treatment means, including but not limited to PDT. Meanwhile, this study offers ideas to the production of artificial substitutes of packed RBCs for clinical blood transfusion.
- 17 July 2018
- Published by Wiley in Advanced Materials
- Vol. 30 (35) , e1802006
Top Cited PapersAggressive Man‐Made Red Blood Cells for Hypoxia‐Resistant Photodynamic Therapy
Extreme hypoxia of tumors represents the most notable barrier against the advance of tumor treatments. Inspired by the biological nature of red blood cells (RBCs) as the primary oxygen supplier in mammals, an aggressive man‐made RBC (AmmRBC) is created to combat the hypoxia‐mediated resistance of tumors to photodynamic therapy (PDT). Specifically, the complex formed between hemoglobin and enzyme‐mimicking polydopamine, and polydopamine‐carried photosensitizer is encapsulated inside the biovesicle that is engineered from the recombined RBC membranes. The mean corpuscular hemoglobin of AmmRBCs reaches about tenfold as high as that of natural RBCs. Owing to the same origin of outer membranes, AmmRBCs share excellent biocompatibility with parent RBCs. The introduced polydopamine plays the role of the antioxidative enzymes existing inside RBCs to effectively prevent the oxygen‐carrying hemoglobin from the oxidation damage during the circulation. This biomimetic engineering can accumulate in tumors, permit in situ efficient oxygen supply, and impose strong PDT efficacy toward the extremely hypoxic tumor with complete tumor elimination. The man‐made pseudo‐RBC shows potentials as a universal oxygen‐self‐supplied platform to sensitize hypoxia‐limited tumor treatment means, including but not limited to PDT. Meanwhile, this study offers ideas to the production of artificial substitutes of packed RBCs for clinical blood transfusion.